SEC Seal
SEC Banner
Search the Next-Generation EDGAR System
Filing Detail
Form SC 13D - General statement of acquisition of beneficial ownership:
SEC Accession No. 0001785982-20-000543
Filing Date
2020-06-15
Accepted
2020-06-15 13:50:17
Documents
10

Document Format Files

Seq Description Document Type Size
1 SCHEDULE 13D (SF) sh13d.htm SC 13D 46356
2 MAY 1, 2020 ex1.htm EX-1 17388
3 ex2.htm EX-2 37232
4 IR/CONSULTING AGREEMENT ex3.htm EX-3 28668
5 GRAPHIC img001_v1.jpg GRAPHIC 22737
6 GRAPHIC img002_v1.jpg GRAPHIC 9358
7 GRAPHIC img003_v1.jpg GRAPHIC 8590
8 GRAPHIC img004_v1.jpg GRAPHIC 13991
9 GRAPHIC img005_v1.jpg GRAPHIC 7052
10 GRAPHIC img006_v1.jpg GRAPHIC 17397
  Complete submission text file 0001785982-20-000543.txt   241037
Mailing Address C/O BIOXYTRAN, INC. 233 NEEDHAM ST, SUITE 300 NEWTON MA 02464
Business Address C/O BIOXYTRAN, INC. 233 NEEDHAM ST, SUITE 300 NEWTON MA 02464 617-494-1199
BIOXYTRAN, INC (Subject) CIK: 0001445815 (see all company filings)

IRS No.: 262797630 | State of Incorp.: NV | Fiscal Year End: 1231
Type: SC 13D | Act: 34 | File No.: 005-84839 | Film No.: 20962779
SIC: 2834 Pharmaceutical Preparations

Mailing Address 1905 S AUDUBON CT SPOKANE WA 99224
Business Address
Sheikh Michael (Filed by) CIK: 0001640636 (see all company filings)

Type: SC 13D